Ebselen Inhibits Hepatitis C Virus NS3 Helicase Binding to Nucleic Acid and Prevents Viral Replication

被引:71
作者
Mukherjee, Sourav [1 ]
Weiner, Warren S. [3 ]
Schroeder, Chad E. [3 ]
Simpson, Denise S. [3 ]
Hanson, Alicia M. [1 ]
Sweeney, Noreena L. [1 ]
Marvin, Rachel K. [2 ]
Ndjomou, Jean [1 ]
Kolli, Rajesh [1 ]
Isailovic, Dragan [2 ]
Schoenen, Frank J. [3 ]
Frick, David N. [1 ]
机构
[1] Univ Wisconsin, Dept Chem & Biochem, Milwaukee, WI 53211 USA
[2] Univ Toledo, Dept Chem & Biochem, Toledo, OH 43606 USA
[3] Univ Kansas, Specialized Chem Ctr, Lawrence, KS 66047 USA
基金
美国国家卫生研究院;
关键词
RNA HELICASE; MUTATIONAL ANALYSIS; TRYPANOSOMA-BRUCEI; LIFE-CYCLE; INFECTION; HCV; PROTEIN; IDENTIFICATION; HEXOKINASE; MECHANISM;
D O I
10.1021/cb500512z
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The hepatitis C virus (HCV) nonstructural protein 3 (NS3) is both a protease, which cleaves viral and host proteins, and a helicase that separates nucleic acid strands, using ATP hydrolysis to fuel the reaction. Many antiviral drugs, and compounds in clinical trials, target the NS3 protease, but few helicase inhibitors that function as antivirals have been reported. This study focuses on the analysis of the mechanism by which ebselen (2-phenyl-1,2-benzisoselenazol-3-one), a compound previously shown to be a HCV antiviral agent, inhibits the NS3 helicase. Ebselen inhibited the abilities of NS3 to unwind nucleic acids, to bind nucleic acids, and to hydrolyze ATP, and about 1 mu M ebselen was sufficient to inhibit each of these activities by 50%. However, ebselen had no effect on the activity of the NS3 protease, even at 100 times higher ebselen concentrations. At concentrations below 10 mu M, the ability of ebselen to inhibit HCV helicase was reversible, but prolonged incubation of HCV helicase with higher ebselen concentrations led to irreversible inhibition and the formation of covalent adducts between ebselen and all 14 cysteines present in HCV helicase. Ebselen analogues with sulfur replacing the selenium were just as potent HCV helicase inhibitors as ebselen, but the length of the linker between the phenyl and benzisoselenazol rings was critical. Modifications of the phenyl ring also affected compound potency over 30-fold, and ebselen was a far more potent helicase inhibitor than other, structurally unrelated, thiol-modifying agents. Ebselen analogues were also more effective antiviral agents, and they were less toxic to hepatocytes than ebselen. Although the above structure-activity relationship studies suggest that ebselen targets a specific site on NS3, we were unable to confirm binding to either the NS3 ATP binding site or nucleic acid binding cleft by examining the effects of ebselen on NS3 proteins lacking key cysteines.
引用
收藏
页码:2393 / 2403
页数:11
相关论文
共 41 条
  • [1] Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
    Bacon, Bruce R.
    Gordon, Stuart C.
    Lawitz, Eric
    Marcellin, Patrick
    Vierling, John M.
    Zeuzem, Stefan
    Poordad, Fred
    Goodman, Zachary D.
    Sings, Heather L.
    Poordad, Fred
    Goodman, Zachary D.
    Sings, Heather L.
    Boparai, Navdeep
    Burroughs, Margaret
    Brass, Clifford A.
    Albrecht, Janice K.
    Esteban, Rafael
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) : 1207 - 1217
  • [2] Observations on screening-based research and some concerning trends in the literature
    Baell, Jonathan B.
    [J]. FUTURE MEDICINAL CHEMISTRY, 2010, 2 (10) : 1529 - 1546
  • [3] Belon CA, 2011, HEPATITIS C: ANTIVIRAL DRUG DISCOVERY AND DEVELOPMENT, P237
  • [4] Fuel Specificity of the Hepatitis C Virus NS3 Helicase
    Belon, Craig A.
    Frick, David N.
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2009, 388 (04) : 851 - 864
  • [5] Monitoring helicase activity with molecular beacons
    Belon, Craig A.
    Frick, David N.
    [J]. BIOTECHNIQUES, 2008, 45 (04) : 433 - +
  • [6] A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle
    Chockalingam, Karuppiah
    Simeon, Rudo L.
    Rice, Charles M.
    Chen, Zhilei
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (08) : 3764 - 3769
  • [7] Novel alternative for the N-N bond formation through a PIFA-mediated oxidative cyclization and its application to the synthesis of indazol-3-ones
    Correa, A
    Tellitu, I
    Dominguez, E
    SanMartin, R
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 2006, 71 (09) : 3501 - 3505
  • [8] The design of drugs for HIV and HCV
    De Clercq, Erik
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (12) : 1001 - 1018
  • [9] EXPEDIENT SYNTHESIS OF EBSELEN AND RELATED-COMPOUNDS
    ENGMAN, L
    HALLBERG, A
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 1989, 54 (12) : 2964 - 2966
  • [10] Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen
    Favrot, Lorenza
    Grzegorzewicz, Anna E.
    Lajiness, Daniel H.
    Marvin, Rachel K.
    Boucau, Julie
    Isailovic, Dragan
    Jackson, Mary
    Ronning, Donald R.
    [J]. NATURE COMMUNICATIONS, 2013, 4